SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 28, Issue 8, 2010, Pages

Comment on pegylated liposomal doxorubicin plus docetaxel in metastatic breast cancer

(2) Smith, Thomas J a Hillner, Bruce E a

a VIRGINIA COMMONWEALTH UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; TAXOID;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; LETTER; METASTASIS; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT OUTCOME; BREAST TUMOR; FEMALE; NOTE; PATHOLOGY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; NEOPLASM METASTASIS; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77950490974 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2009.26.8243 Document Type: Letter

Times cited : (3)

References (8)

1
- 76749156249
- Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study
- Sparano JA, Makhson AN, Semiglazov VF, et al: Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study. J Clin Oncol 27:4522-4529, 2009
- (2009) J Clin Oncol , vol.27 , pp. 4522-4529
- Sparano, J.A.¹ Makhson, A.N.² Semiglazov, V.F.³

2
- 36849071808
- Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
- DOI 10.1200/JCO.2007.12.6557
- Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007 (Pubitemid 350232252)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.33 , pp. 5210-5217
- Thomas, E.S.¹ Gomez, H.L.² Li, R.K.³ Chung, H.-C.⁴ Fein, L.E.⁵ Chan, V.F.⁶ Jassem, J.⁷ Pivot, X.B.⁸ Klimovsky, J.V.⁹ De, M.F.H.¹⁰ Xu, B.¹¹ Campone, M.¹² Lerzo, G.L.¹³ Peck, R.A.¹⁴ Mukhopadhyay, P.¹⁵ Vahdat, L.T.¹⁶ Roche, H.H.¹⁷

3
- 70049100788
- International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy
- Cardoso F, Bedard PL, Winer EP, et al: International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101:1174-1181, 2009
- (2009) J Natl Cancer Inst , vol.101 , pp. 1174-1181
- Cardoso, F.¹ Bedard, P.L.² Winer, E.P.³

4
- 50549096593
- Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
- Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950-3957, 2008
- (2008) J Clin Oncol , vol.26 , pp. 3950-3957
- Albain, K.S.¹ Nag, S.M.² Calderillo-Ruiz, G.³

5
- 0037096755
- Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
- DOI 10.1200/JCO.2002.09.002
- O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002 (Pubitemid 34651510)
- (2002) Journal of Clinical Oncology , vol.20 , Issue.12 , pp. 2812-2823
- O'Shaughnessy, J.¹ Miles, D.² Vukelia, S.³ Moiseyenko, V.⁴ Ayoub, J.-P.⁵ Cervantes, G.⁶ Fumoleau, P.⁷ Jones, S.⁸ Lui, W.-Y.⁹ Mauriac, L.¹⁰ Twelves, C.¹¹ Van, H.G.¹² Verma, S.¹³ Leonard, R.¹⁴

6
- 9044233642
- Outcomes of cancer treatment for technology assessment and cancer treatment guidelines: American Society of Clinical Oncology
- Outcomes of cancer treatment for technology assessment and cancer treatment guidelines: American Society of Clinical Oncology. J Clin Oncol 14:671-679, 1996
- (1996) J Clin Oncol , vol.14 , pp. 671-679

7
- 65549153613
- Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing
- Hillner BE, Smith TJ: Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 27:2111-2113, 2009
- (2009) J Clin Oncol , vol.27 , pp. 2111-2113
- Hillner, B.E.¹ Smith, T.J.²

8
- 65549125891
- Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
- Reed SD, Li Y, Anstrom KJ, Schulman KA: Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 27:2185-2191, 2009
- (2009) J Clin Oncol , vol.27 , pp. 2185-2191
- Reed, S.D.¹ Li, Y.² Anstrom, K.J.³ Schulman, K.A.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.